A study by two psychologists at Germany’s Max Planck Institute on Human Development poured cold water on the use of brain electrical stimulation techniques, lending support to those who dismiss the methods of supposedly improving memory and mood as pseudoscience.
Amid growing evidence that mammography alone is not sufficient in screening women with dense breast tissue for breast cancer, a new Mayo Clinic study shows that adding an innovative molecular breast imaging solution to traditional mammography could be more accurate and cost-effective.
The FDA said international standards were insufficient, and put forth a stricter standard in order to ensure that intraocular lenses and other intraocular ophthalmic devices are free of bacteria upon manufacturing.
A new fetal electrocardiogram (ECG) technology designed to be used along with conventional fetal heart rate monitoring contributes little benefit in reducing complications during childbirth, according to a study by the National Institutes of Health.
The FDA touted faster approval times in a report on policies and initiatives at its device arm (CDRH). In addition, the agency outlined some of its new regulatory initiatives.
If you are still using FMEA as your methodology to capture medical device risk management activities, then your risk management process is out of date.
The Framingham Heart Study has revolutionized cardiology over the decades, leading to insights like the dangers of smoking in the 1960s, elevated blood pressure in the 1970s and more recently, genomic risk factors. Another Massachusetts study is underway, with the intention of becoming the equivalent study in the orthopedics arena, according to Dr. David Ayers, chair of the orthopedics department at the University of Massachusetts Medical School in Worcester.
Google is divvying up its composite parts, becoming, depending on whom you ask, the new Berkshire Hathaway, the next General Electric or something heretofore never seen. However, the move could have mixed implications for Google’s nascent but growing life sciences empire — including the high-profile, secretive biotech Calico–as shuffling things around could expose such moonshot projects to the pitchforks of profit-hungry investors.
Google has been scouting out promising med tech projects since launching its life sciences division a couple of years ago, inking deals to expand its reach in patient monitoring and wearable health. In its latest foray the company will work with Dexcom to develop cheaper, miniaturized glucose monitors, combining its electronics platform with Dexcom’s sensor technology to improve care for patients.
Pennsylvania drugmaker Zynerba Pharmaceuticals is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $42 million in an IPO.